These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 2345310)
1. Prophylactic immunization against experimental Leishmania donovani infection by use of a purified protein vaccine. White AC; McMahon-Pratt D J Infect Dis; 1990 Jun; 161(6):1313-4. PubMed ID: 2345310 [No Abstract] [Full Text] [Related]
2. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Ghosh A; Zhang WW; Matlashewski G Vaccine; 2001 Oct; 20(1-2):59-66. PubMed ID: 11567746 [TBL] [Abstract][Full Text] [Related]
3. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin. Mukherjee M; Bhattacharyya A; Duttagupta S Med Sci Monit; 2002 Apr; 8(4):BR117-22. PubMed ID: 11951057 [TBL] [Abstract][Full Text] [Related]
4. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Sukumaran B; Tewary P; Saxena S; Madhubala R Vaccine; 2003 Mar; 21(11-12):1292-9. PubMed ID: 12559811 [TBL] [Abstract][Full Text] [Related]
5. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Paraguai de Souza E; Bernardo RR; Palatnik M; Palatnik de Sousa CB Vaccine; 2001 Apr; 19(23-24):3104-15. PubMed ID: 11312005 [TBL] [Abstract][Full Text] [Related]
6. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis. Das P; Paik D; Naskar K; Chakraborti T Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116 [TBL] [Abstract][Full Text] [Related]
7. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Melby PC; Yang J; Zhao W; Perez LE; Cheng J Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143 [TBL] [Abstract][Full Text] [Related]
9. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection. Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224 [TBL] [Abstract][Full Text] [Related]
10. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Mazumdar T; Anam K; Ali N Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644 [TBL] [Abstract][Full Text] [Related]
11. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Afrin F; Rajesh R; Anam K; Gopinath M; Pal S; Ali N Infect Immun; 2002 Dec; 70(12):6697-706. PubMed ID: 12438344 [TBL] [Abstract][Full Text] [Related]
12. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803 [TBL] [Abstract][Full Text] [Related]
13. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection. Daifalla NS; Bayih AG; Gedamu L Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023 [TBL] [Abstract][Full Text] [Related]
14. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. Rachamim N; Jaffe CL J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215 [TBL] [Abstract][Full Text] [Related]
15. Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice. Yam KK; Hugentobler F; Pouliot P; Stern AM; Lalande JD; Matlashewski G; Olivier M; Cousineau B J Med Microbiol; 2011 Sep; 60(Pt 9):1248-1260. PubMed ID: 21527547 [TBL] [Abstract][Full Text] [Related]
16. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate. Tandon R; Chandra S; Baharia RK; Misra P; Das S; Rawat K; Siddiqi MI; Sundar S; Dube A Parasitology; 2018 Apr; 145(4):508-526. PubMed ID: 28691653 [TBL] [Abstract][Full Text] [Related]
17. Kinesin motor domain of Leishmania donovani as a future vaccine candidate. Dey A; Sharma P; Redhu NS; Singh S Clin Vaccine Immunol; 2008 May; 15(5):836-42. PubMed ID: 18353921 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis. Thakur A; Kaur H; Kaur S Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605 [TBL] [Abstract][Full Text] [Related]
19. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani. Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564 [TBL] [Abstract][Full Text] [Related]
20. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Afrin F; Ali N Infect Immun; 1997 Jun; 65(6):2371-7. PubMed ID: 9169776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]